Amaia Esquisabel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amaia Esquisabel has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- José Luis Pedraz
NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain
16 shared publications Marta Pastor
BioPraxis Research AIE, R&D Department, Miñano (Araba), Spain
7 shared publications- Rosa Maria Hernandez
NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain
7 shared publications - Manoli Igartua
NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, Vitoria-Gasteiz 01006, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, Madrid 28029, Spain; Bioaraba, NanoBioCel Research Group, Vitoria-Gasteiz 01006, Spain
6 shared publications M. Pastor
A NanoBioCel Group, Laboratory of Pharmaceutics , School of Pharmacy, University of the Basque Country (UPV/EHU) , Vitoria-Gasteiz , Spain
5 shared publications- Alicia Rodríguez-Gascón
Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country EHU, Paseo de la Universidad n° 7, 01006 Vitoria-Gasteiz, Spain
4 shared publications
Latest Publications
- 1 June 2019
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 18, 101-111
Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration
- 1 June 2019
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 18, 101-111
Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration
- Open Access
- 12 March 2018
- Published by EHU Press in EKAIA Euskal Herriko Unibertsitateko Zientzia eta Teknologia Aldizkaria
- No. 33,p. 35-53
KOSMETIKA ONKOLOGIKOA: kimioterapiak eta erradioterapiak larruazalean eragindako efektu desiragaitzak eta horiek tratatzeko konposatu naturaletan oinarritutako formulazio berriak
Sarritan, tratamendu onkologikoek pazientearen bizi-kalitatea baldintzatu dezaketen efektu desiragaitzak sortzen dituzte, minbizi-zelulak kaltetzeaz gain, bestelako ehun osasuntsuak suntsitzen baitituzte. Lan honetan tratamendu onkologikoen ondorioz larruazalean sortutako gaitzak aztertuko dira (hala nola pruritoa, ezkatatzea edota ultzerazioa kasu larrienetan) eta baita arazo horiei aurre egiteko formulatu diren produktu berrien konposizioa ere. Orain arte erabili diren kortikoide, antihistaminiko edo lidokainadun kremak alde batera uzteko helburuarekin, laborategi dermokosmetikoek paziente onkologikoen larruazala tratatzeko bestelako produktu-lerroak merkaturatu dituzte, horien bizi-kalitatea hobetu eta eragin desiragaitz berantiarren agerpena oztopatzeko asmoz. Antzinatik erabili izan diren landare-estraktuez baliatuz, larruazalaren erreparaketa-prozesua bultzatzea helburu duten formulazioak diseinatu dituzte, Maria D’uol edota OnCosmetics laborategien produktu-lerroak bezala. Beste kasu batzuetan, landare-jatorriko konposatuez gain, bestelako molekula aktiboak erabili dituzte; hala nola, BEACON Biomedicine laborategien kasuan, hazkuntza-faktoreak eta Tectum 11 izeneko proteina-konplexuak erabiltzen dituzte, edota IFC laborategian, Cryptomphalus aspersa barraskilotik lortutako jariakinaz baliatzen dira tratamendu onkologikoen ondorioz sortutako larruazaleko gaitzak erreparatzeko.
- 12 March 2018
- Published by EHU Press in EKAIA Euskal Herriko Unibertsitateko Zientzia eta Teknologia Aldizkaria
- No. 33,p. 35-53
Open AccessKOSMETIKA ONKOLOGIKOA: kimioterapiak eta erradioterapiak larruazalean eragindako efektu desiragaitzak eta horiek tratatzeko konposatu naturaletan oinarritutako formulazio berriak
Sarritan, tratamendu onkologikoek pazientearen bizi-kalitatea baldintzatu dezaketen efektu desiragaitzak sortzen dituzte, minbizi-zelulak kaltetzeaz gain, bestelako ehun osasuntsuak suntsitzen baitituzte. Lan honetan tratamendu onkologikoen ondorioz larruazalean sortutako gaitzak aztertuko dira (hala nola pruritoa, ezkatatzea edota ultzerazioa kasu larrienetan) eta baita arazo horiei aurre egiteko formulatu diren produktu berrien konposizioa ere. Orain arte erabili diren kortikoide, antihistaminiko edo lidokainadun kremak alde batera uzteko helburuarekin, laborategi dermokosmetikoek paziente onkologikoen larruazala tratatzeko bestelako produktu-lerroak merkaturatu dituzte, horien bizi-kalitatea hobetu eta eragin desiragaitz berantiarren agerpena oztopatzeko asmoz. Antzinatik erabili izan diren landare-estraktuez baliatuz, larruazalaren erreparaketa-prozesua bultzatzea helburu duten formulazioak diseinatu dituzte, Maria D’uol edota OnCosmetics laborategien produktu-lerroak bezala. Beste kasu batzuetan, landare-jatorriko konposatuez gain, bestelako molekula aktiboak erabili dituzte; hala nola, BEACON Biomedicine laborategien kasuan, hazkuntza-faktoreak eta Tectum 11 izeneko proteina-konplexuak erabiltzen dituzte, edota IFC laborategian, Cryptomphalus aspersa barraskilotik lortutako jariakinaz baliatzen dira tratamendu onkologikoen ondorioz sortutako larruazaleko gaitzak erreparatzeko.
- Open Access
- 8 November 2017
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 97 (5) , 1469-1476
Benznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease
This article describes the characterization of various encapsulated formulations of benznidazole, the current first-line drug for the treatment of Chagas disease. Given the adverse effects of benznidazole, safer formulations of this drug have a great interest. In fact, treatment of Chagas disease with benznidazole has to be discontinued in as much as 20% of cases due to side effects. Furthermore, modification of delivery and formulations could have potential effects on the emergence of drug resistance. The trypanocidal activity of new nanostructured formulations of benznidazole to eliminate Trypanosoma cruzi was studied in vitro as well as their toxicity in two cultured mammalian cell lines (HepG2 and Fibroblasts). Nanoparticles tested included nanostructured lipid carriers, solid lipid nanoparticles, liposomes, quatsomes, and cyclodextrins. The in vitro cytotoxicity of cyclodextrins–benznidazole complexes was significantly lower than that of free benznidazole, whereas their trypanocidal activity was not hampered. These results suggest that nanostructured particles may offer improved therapeutics for Chagas disease.
- 8 November 2017
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 97 (5) , 1469-1476
Open AccessBenznidazole Nanoformulates: A Chance to Improve Therapeutics for Chagas Disease
This article describes the characterization of various encapsulated formulations of benznidazole, the current first-line drug for the treatment of Chagas disease. Given the adverse effects of benznidazole, safer formulations of this drug have a great interest. In fact, treatment of Chagas disease with benznidazole has to be discontinued in as much as 20% of cases due to side effects. Furthermore, modification of delivery and formulations could have potential effects on the emergence of drug resistance. The trypanocidal activity of new nanostructured formulations of benznidazole to eliminate Trypanosoma cruzi was studied in vitro as well as their toxicity in two cultured mammalian cell lines (HepG2 and Fibroblasts). Nanoparticles tested included nanostructured lipid carriers, solid lipid nanoparticles, liposomes, quatsomes, and cyclodextrins. The in vitro cytotoxicity of cyclodextrins–benznidazole complexes was significantly lower than that of free benznidazole, whereas their trypanocidal activity was not hampered. These results suggest that nanostructured particles may offer improved therapeutics for Chagas disease.
- 1 April 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (4) , e01912-16
Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials
Despite its toxicity and low efficacy in the chronic phase, benznidazole is the drug of choice in Chagas disease. Scarce information about pharmacokinetics and pharmacodynamics of benznidazole has been published. We performed a phase I, open-label, nonrandomized pharmacokinetic study of benznidazole (Abarax) conducted with 8 healthy adult volunteers at the Infectious Diseases Department of the Vall d'Hebron University Hospital (Barcelona, Spain). The separation and detection of benznidazole were performed on a Waters Acquity ultraperformance liquid chromatography system (UPLC) coupled with a Waters Xevo TQ MS triple quadrupole mass spectrometer. The pharmacokinetic parameters were calculated based on a noncompartmental body model using Phoenix WinNonlin version 6.3 software. Furthermore, computational simulations were calculated for the multiple-dose administration at two dose regimens: 100 mg of benznidazole administered every 8 h and 150 mg of benznidazole administered every 12 h. After benznidazole administration, the median area under the concentration-time curve from time zero to timet(AUC0–t) and extrapolated to infinity (AUC0–∞) were about 46.4 μg · h/ml and 48.4 μg · h/ml, respectively. Plasma benznidazole concentrations peaked at 3.5 h, with maximal concentrations of 2.2 μg/ml, and benznidazole exhibited a terminal half-life of 12.1 h. The median maximum concentration (Cmax) of benznidazole was lower in men than in women (1.6 versus 2.9 μg/ml), and median volume of distribution (V) as a function of bioavailability (F) was higher in men than in women (125.9 versus 88.6 liters). In conclusion, dose regimens (150 mg/12 h or 100 mg/8 h) reached a steady-state range concentration above of the minimum experimental therapeutic dose. Sex differences in the benznidazole pharmacokinetics were observed; mainly, men had lowerCmaxand higherV/Fthan women.
- 1 April 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (4) , e01912-16
Pharmacokinetics of Benznidazole in Healthy Volunteers and Implications in Future Clinical Trials
Despite its toxicity and low efficacy in the chronic phase, benznidazole is the drug of choice in Chagas disease. Scarce information about pharmacokinetics and pharmacodynamics of benznidazole has been published. We performed a phase I, open-label, nonrandomized pharmacokinetic study of benznidazole (Abarax) conducted with 8 healthy adult volunteers at the Infectious Diseases Department of the Vall d'Hebron University Hospital (Barcelona, Spain). The separation and detection of benznidazole were performed on a Waters Acquity ultraperformance liquid chromatography system (UPLC) coupled with a Waters Xevo TQ MS triple quadrupole mass spectrometer. The pharmacokinetic parameters were calculated based on a noncompartmental body model using Phoenix WinNonlin version 6.3 software. Furthermore, computational simulations were calculated for the multiple-dose administration at two dose regimens: 100 mg of benznidazole administered every 8 h and 150 mg of benznidazole administered every 12 h. After benznidazole administration, the median area under the concentration-time curve from time zero to timet(AUC0–t) and extrapolated to infinity (AUC0–∞) were about 46.4 μg · h/ml and 48.4 μg · h/ml, respectively. Plasma benznidazole concentrations peaked at 3.5 h, with maximal concentrations of 2.2 μg/ml, and benznidazole exhibited a terminal half-life of 12.1 h. The median maximum concentration (Cmax) of benznidazole was lower in men than in women (1.6 versus 2.9 μg/ml), and median volume of distribution (V) as a function of bioavailability (F) was higher in men than in women (125.9 versus 88.6 liters). In conclusion, dose regimens (150 mg/12 h or 100 mg/8 h) reached a steady-state range concentration above of the minimum experimental therapeutic dose. Sex differences in the benznidazole pharmacokinetics were observed; mainly, men had lowerCmaxand higherV/Fthan women.
- 2 October 2016
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 33 (7) , 636-645
Stability study of sodium colistimethate-loaded lipid nanoparticles
In the last decades, the encapsulation of antibiotics into nanoparticulate carriers has gained increasing attention for the treatment of infectious diseases. Sodium colistimethate-loaded solid lipid nanoparticles (Colist-SLNs) and nanostructured lipid carriers (Colist-NLCs) were designed aiming to treat the pulmonary infection associated to cystic fibrosis patients. The nanoparticles were freeze-dried using trehalose as cryoprotectant. The stability of both nanoparticles was analysed over one year according to the International Conference of Harmonisation (ICH) guidelines by determining the minimum inhibitory concentration (MIC) against clinically isolated Pseudomonas aeruginosa strains and by studying their physico-chemical characteristics. The results showed that Colist-SLNs lost their antimicrobial activity at the third month; on the contrary, the antibacterial activity of Colist-NLCs was maintained throughout the study within an adequate range (MIC ≤16 μg/mL). In addition, Colist-NLCs exhibited suitable physico-chemical properties at 5 °C and 25 °C/60% relative humidity over one year. Altogether, Colist-NLCs proved to have better stability than Colist-SLNs.
- 2 October 2016
- Published by Taylor & Francis in Journal of Microencapsulation
- Vol. 33 (7) , 636-645
Stability study of sodium colistimethate-loaded lipid nanoparticles
In the last decades, the encapsulation of antibiotics into nanoparticulate carriers has gained increasing attention for the treatment of infectious diseases. Sodium colistimethate-loaded solid lipid nanoparticles (Colist-SLNs) and nanostructured lipid carriers (Colist-NLCs) were designed aiming to treat the pulmonary infection associated to cystic fibrosis patients. The nanoparticles were freeze-dried using trehalose as cryoprotectant. The stability of both nanoparticles was analysed over one year according to the International Conference of Harmonisation (ICH) guidelines by determining the minimum inhibitory concentration (MIC) against clinically isolated Pseudomonas aeruginosa strains and by studying their physico-chemical characteristics. The results showed that Colist-SLNs lost their antimicrobial activity at the third month; on the contrary, the antibacterial activity of Colist-NLCs was maintained throughout the study within an adequate range (MIC ≤16 μg/mL). In addition, Colist-NLCs exhibited suitable physico-chemical properties at 5 °C and 25 °C/60% relative humidity over one year. Altogether, Colist-NLCs proved to have better stability than Colist-SLNs.
- 1 September 2016
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15 (5) , 611-618
Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients
- 1 September 2016
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 15 (5) , 611-618
Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients
- 25 March 2016
- Published by Springer Nature
- p. 453-487
The Use of Nanoparticles for Antimicrobial Delivery
- 25 March 2016
- Published by Springer Nature
- p. 453-487
The Use of Nanoparticles for Antimicrobial Delivery
- 1 February 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 498 (1-2) , 263-273
Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis
- 1 February 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 498 (1-2) , 263-273
Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis
- Open Access
- 22 July 2015
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (11) , 2945-2955
Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy
As the WHO stated, lower respiratory infections are the third leading cause of death. In addition, it is remarkable that antimicrobial resistance represents a huge threat. Thus, new therapeutic weapons are required. Among the possible alternatives, antibiotic encapsulation in nanoparticles has gained much attention in terms of improved tolerability, activity and ability to combat the resistance mechanisms of bacteria. In this regard, this review article focuses on the latest nanocarrier approaches for inhalatory therapy of antibiotics. First, the technology related to lung disposition will be reviewed. Then, nanocarrier systems will be introduced and the challenges required to perform adequate pulmonary deposition analysed. In the following part, drug delivery systems (DDSs) on the market or in clinical trials are described and, finally, new approaches of nanoparticles that have reached pre-clinical stage are enumerated. Altogether, this review aims at gathering together the novel nanosystems for anti-infectious therapy, underlining the potential of DDSs to improve and optimize currently available antibiotic therapies in the context of lung infections.
- 22 July 2015
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 70 (11) , 2945-2955
Open AccessPulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy
As the WHO stated, lower respiratory infections are the third leading cause of death. In addition, it is remarkable that antimicrobial resistance represents a huge threat. Thus, new therapeutic weapons are required. Among the possible alternatives, antibiotic encapsulation in nanoparticles has gained much attention in terms of improved tolerability, activity and ability to combat the resistance mechanisms of bacteria. In this regard, this review article focuses on the latest nanocarrier approaches for inhalatory therapy of antibiotics. First, the technology related to lung disposition will be reviewed. Then, nanocarrier systems will be introduced and the challenges required to perform adequate pulmonary deposition analysed. In the following part, drug delivery systems (DDSs) on the market or in clinical trials are described and, finally, new approaches of nanoparticles that have reached pre-clinical stage are enumerated. Altogether, this review aims at gathering together the novel nanosystems for anti-infectious therapy, underlining the potential of DDSs to improve and optimize currently available antibiotic therapies in the context of lung infections.
- 1 December 2014
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 477 (1-2) , 485-494
Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis
- 1 December 2014
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 477 (1-2) , 485-494
Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis